

Nomad Bioscience



inspired by nature & tribal wisdom

Food Antibacterials



The Threat of contaminated food



In USA, foodborne diseases affect 50 million people yearly, with 56.000 hospitalizations, 3.000 deaths a year

The most costly and deadly pathogen accounting for 35% of

hospitalizations and 28% deaths is Salmonella

In EU - second most common pathogen and the main cause of food poisoning outbreaks

Main sources of pathogen: contaminated eggs, poultry and pig meat

25-40% of meat sold in supermarkets contains Salmonella


Not declared as a food adulterant (because lack of effective control);

antibiotics are banned in animal husbandry & processing)









Number of Cases in the USA Reported to the CDC

- removing all pathogenic bacteria in our food specifically without harming our beneficial gut microflora or changing taste, and without antibiotics
- eliminating the main cause of deaths and costly hospitalizations
 caused by foodborne bacteria
- Treating the food during processing or killing bad bacteria in animals prior to harvesting
- opportunity to build a high value, sustainable, novel food company



Bacteriocins

non-antibiotic biologics invented by nature

- Evolved by nature and used by bacteria themselves to fight related germs
- Up to one million times more active than antibiotics, completely safe for humans and animals, and easy to produce in green plants
- Highly specific, killing just one bacterial species
- Huge diversity of bacteriocins in bacterial genomes, with different mechanisms of action
- Active on all multi-drug resistant bacteria





Achievements

with 12 million in equity financing since 2011





- We mined extensively bacterial genomes and identified protein candidates that:
 - are highly active against all Salmonella pathovars
 - are highly active against *Escherichia coli O157:H7*, 'Big Seven' pathovars
 - Have high potency in vitro, on food matrices and in live animals
- Five FDA GRAS registrations for bacteriocins as antibacterials in USA secured, with registration in other countries/regions ongoing
- Developed a scalable manufacturing process; conducted open field and greenhouse studies; started pilot scale production in 2021 in Spain
- Expanded dominant IP position. Filed major patents to assure broad exclusivity


Bacteriocins



mined and extensively researched by our scientists







First-In-Class Regulatory Approvals



- GRAS ('Generally Recognized As Safe') is a regulatory approval path for food substances in USA, the largest market
- Five GRAS regulatory approvals for products secured, two in preparation
- Products approved as food processing aids (no need for labelling)
- Approvals for treatment of live animals (removal of bacteria before harvesting) in development
- Nomad intends to seek approvals in other important regions/countries: EU, Japan, China
- Approvals for our products in new markets (e.g. veterinary medicines) are being explored



Nomad's bacteriocins - GRAS submissions/acceptances*

Product/Origin	GRAS GRN	Submission date	Response date
Colicins/Escherichia coli	000593	07.2015	12.2015/FDA
Colicins/E.coli	000676	11.2016	05.2017/FDA 01.2017/USDA
Nicotiana as a GRAS host	000775	04.2018	10.2018/FDA
Salmocins/ Salmonella enterica	000824	11.2018	10.2019/FDA 10.2020/USDA
Endolysins, Clostridium phages	000802	07.2018	04.2019/FDA
Salmocins/live animals	XXX	06.2022	est. 12.2022/FDA
Colicins/live animals	XXX	12.2022	est. 06.2023/FDA

^{*}All approved bacteriocins are 'food processing aids'.
Colicins & Salmocins also listed in USDA/FSIS Directive 7120.1

Our Lead Product: NMW 02 Salmocin





- NMW02 for control of Salmonella in processing of poultry, swine, fish meat and eggs as food processing aid
- Natural protein, non-antibiotic, the most potent known bacteriocin, active in nanomolar concentrations
- Broadly active against all Salmonella pathovars
- Safe, doesn't damage natural gut microbiome, plant-made
- Breakthrough product: no control of Salmonella in food chain today
- 180 1.990 million potential market (USA only) food processing plus treatment of live animals
- Approved in USA by FDA and USDA
- NAMBAWAN intends to have NMW 02 on the U.S. market by 2024



Strategy



- Develop green plant hosts with economically superior high content of bacteriocins controlling Salmonella and STEC Escherichia coli
- Develop industrial versions of producer plant cultivation in open field and greenhouse, along with a scalable GMP-certified purification process, secure necessary manufacturing licenses
- Secure long-term commercial agreements with contract plant growers and CMOs, enter market by Q4 2024 or earlier
- Continue and expand number of potential strategic clients by providing test product samples and negotiating partnership agreements; expand the team; be ready for exit through trade sale or going public





Next

between now and Q4 2024

- We intend to have NMW 02 Salmocin (Salmonella control) product as food processing aid on the U.S. market in 2024
- Ongoing process of registering NMW 02 beyond USA
- Development of NMW 03 Colicin (E. coli control) product as food processing aid on the U.S. market (2025)
- Development of Salmocin NMW 04 as animal food substance for cleansing animals (chickens, pigs) prior to harvest
- Collaboration with world top three veterinary company; interest from world top five meat processor







NAMBAWAN's Pipeline Q1 2022 - Q4 2024*











is a spin-off of NOMAD Bioscience

Reg. R&D Industrial Product Pilot approval NMW 01 Thaumatin 2 (sweetener, taste modifier) **NMW 02** Salmonella control A (meats, fish, eggs, produce) **NMW 03** Escherichia coli control B (meats, fish, eggs, produce) **NMW 04** Salmonella control C (live chickens, swine Brazzein 3 NMW 05 (sweetener, taste modifier) 12,2024

*NMW 01 & NMW 05 are pipeline optionalities





Pilot Production

Extremadura, Spain, 2021









Summary

NAMBAWAN is a pioneering developer, and soon, producer of natural non-antibiotic antibacterials for broad control of *Salmonella* and *Escherichia coli* in food products



State of the art green technologies with strong IP



Risk-hedged pipeline of approved product candidates



Strong team, board and scientific advisors



Opportunity for IPO or trade sale as leading food company